- |||||||||| lithium carbonate ER / Generic mfg.
Using a Stem Cell-Derived Model to Repurpose Drugs for Bipolar Disorder () - May 16, 2024 - Abstract #WFSBP2024WFSBP_281;
The hypothesis generating data from the CMap analysis corroborates our idea that using the stem cell-derived in vitro model, we can bypass a fundamental roadblock in therapy development in psychiatry: the lack of singular molecular targets. It allows us to understand how healthy and diseased brains differ in key cell types while retaining the donor
- |||||||||| Predicting Clinical and Functional Outcomes in Chronic Schizophrenia. () - May 16, 2024 - Abstract #WFSBP2024WFSBP_264;
Further analyses will focus on predicting PANSS total at 12 weeks and 18 months, as well as predicting symptomatic remission, functioning and quality of life. Predicting which individuals will have poor clinical and functional outcomes and understanding the underlying factors behind these prediction may provide targets for new interventions and identify the group of patients who are most in need of these interventions.
- |||||||||| risperidone / Generic mfg.
Cerebellar morphometry in schizophrenia: an investigation across different illness stages () - May 16, 2024 - Abstract #WFSBP2024WFSBP_262;
Predicting which individuals will have poor clinical and functional outcomes and understanding the underlying factors behind these prediction may provide targets for new interventions and identify the group of patients who are most in need of these interventions. We recruited three groups of subjects at the National Institute of Mental Health and Neurosciences, Bangalore, India: a clinical group of 54 drug na
- |||||||||| aripiprazole / Generic mfg.
Different Dosage Different Pharmacology (DDDP) () - May 16, 2024 - Abstract #WFSBP2024WFSBP_250;
the more precise our "language" is, the better is our ability to use the pharmacological tools available. DDDP is an example to where this understanding might extend.
- |||||||||| clozapine / Generic mfg.
Translating Psychiatric Genetics to Clinical Applications with Novel Statistical and Machine Learning Approaches () - May 16, 2024 - Abstract #WFSBP2024WFSBP_241;
Using these novel statistical methods, we will not only present the conceptual foundations of these tools, but ground these in a clinically relevant framework and showcase how using these tools can lead to clinically relevant translational science. Speakers from Asia, Europe and North-America will cover new findings in relevant topics, including clozapine metabolism and clozapine-induced agranulocytosis, identification of gene-sets with greater biological specificity associated with mental illness, providing new insights into the pathobiology of complex polygenic disorders, improvements in prediction performance of polygenic hazard score models, and longitudinal findings highlighting how the effect of SNPs change with time to reveal factors relevant for development of mental illness applying longitudinal cohorts.
- |||||||||| aripiprazole / Generic mfg., ketamine / Generic mfg., minocycline / Generic mfg.
Non-Pharmacological and Long-Term Treatments for TRD () - May 16, 2024 - Abstract #WFSBP2024WFSBP_235;
Neuromodulatory interventions such as ECT and TMS ranked highest as far as treatment response of acute episodes are concerned. The results of this trial together with a second comparative meta-analysis on efficacy of DBS will be presented in the talk.
- |||||||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie, Spravato (esketamine intranasal) / J&J, Rexulti (brexpiprazole) / Lundbeck, Otsuka
Update on Treatment Resistant Depression () - May 16, 2024 - Abstract #WFSBP2024WFSBP_231;
Intravenous ketamine and intranasal esketamine (co-administered with an antidepressant) are established as efficacious in the management of TRD. Several second-generation antipsychotics (e.g., aripiprazole, brexpiprazole, cariprazine, quetiapine XR) are proven effective as antidepressant augmentation treatments in partial responders, but only the olanzapine-fluoxetine combination has been studied in FDA-defined TRD...Non-
- |||||||||| clozapine / Generic mfg.
Dysregulations of Endogenous Amino Acids and Related Neurocircuits in Psychiatric Disorders () - May 16, 2024 - Abstract #WFSBP2024WFSBP_197;
Sodium benzoate, targeting DAAO activator (G72)-DAAO-NMDA pathway, antioxidants-anti-inflammatory pathway, and sex hormones, improved clozapine-resistant schizophrenia in a placebo-controlled trial...Sodium benzoate's effects on antioxidants deserves further investigation. 2024 WFSBP Congress
- |||||||||| clozapine / Generic mfg.
Modified Leukocyte Monitoring in clozapine: Proposal by the Dutch Clozapine Collaboration Group () - May 16, 2024 - Abstract #WFSBP2024WFSBP_189;
2024 WFSBP Congress 1) Restrict mandatory monitoring of the absolute neutrophil count (ANC) to the first 18 weeks of clozapine treatment, 2) the prescriber and the well-informed patient decide together about further monitoring frequency, 3) Clozapine treatment must be stopped if the ANC falls below 1.0
- |||||||||| clozapine / Generic mfg.
The Art of Prescribing Clozapine: Novel Developments () - May 16, 2024 - Abstract #WFSBP2024WFSBP_186;
Together, these presentations underscore the importance of personalized, evidence-based approaches in optimizing clozapine treatment for schizophrenia. In this way this symposium hopes to contribute to the removal of hurdles to clozapine treatment.
- |||||||||| clozapine / Generic mfg.
The Association of Anterior Cingulate Cortex Glutamate and Clozapine Eligibility in an Early Psychosis Sample () - May 16, 2024 - Abstract #WFSBP2024WFSBP_153;
While elevated ACC glutamate has been associated with poor antipsychotic response, it is unclear whether elevated glutamate is associated with clozapine eligibility, a clinically meaningful outcome. The ability to prospectively identify clozapine eligibility could lead to reformulation of current guidelines regarding clozapine use and may inform the development of additional treatment options for individuals with treatment resistant schizophrenia.
- |||||||||| risperidone / Generic mfg.
Risperidone Treatment Failure and CYP2D6 genotypes: Results from a One-Year Longitudinal Study. () - May 16, 2024 - Abstract #WFSBP2024WFSBP_142;
Future studies should be performed to confirm the possibilities of using this endogenous biomarker for assessing CYP2D6 phenotypes and for personalizing treatments. Over one year, CYP2D6 PM presented an increasing risk to switch from risperidone over time, the risk becoming statistically significant after the first three months of treatment.
- |||||||||| lithium carbonate ER / Generic mfg.
Mega Cisterna Magna in Early-Onset Bipolar Disorder () - May 16, 2024 - Abstract #WFSBP2024WFSBP_106;
Quetiapine was added to treatment for his persisting delusions and titrated up to 300mg/day... In the presented case, mega cisterna magna may have effects on cerebellar activation.
- |||||||||| fluoxetine / Generic mfg.
Clinical Aspects of Missed ADHD Diagnosis in a Depressive Patient () - May 16, 2024 - Abstract #WFSBP2024WFSBP_96;
Nevertheless, attention deficit hyperactivity disorder (ADHD) remains significantly underdiagnosed. Remarkably, diagnosing and treating ADHD in psychiatric patients transforms their capabilities and significantly enhances their quality of life.
- |||||||||| lithium carbonate ER / Generic mfg.
Suicide Attempt Resulting in Bilateral Leg Amputation: A Case of Early-onset Bipolar Disorder () - May 16, 2024 - Abstract #WFSBP2024WFSBP_81;
Bifrontal ECT has been reported to be effective for patients with refractory mania and aggressive behavior or psychotic symptoms(4). In this case, we emphasize the importance of suicidal risk in BD patients and show that early intervention can be life-saving for patients especially in high-risk groups.
- |||||||||| risperidone / Generic mfg.
Risperidone Treatment Failure and CYP2D6 genotypes: Results from a One-Year Longitudinal Study. () - May 16, 2024 - Abstract #WFSBP2024WFSBP_64;
Future studies should be performed to confirm the possibilities of using this endogenous biomarker for assessing CYP2D6 phenotypes and for personalizing treatments. Over one year, CYP2D6 PM presented an increasing risk to switch from risperidone over time, the risk becoming statistically significant after the first three months of treatment.
- |||||||||| clozapine / Generic mfg.
Journal: Accelerated pace of aging in schizophrenia: Five case-control studies. (Pubmed Central) - May 15, 2024
This may explain the wide-ranging risk among people with schizophrenia for developing multiple different age-related physical diseases, including metabolic, respiratory, and cardiovascular diseases, and dementia. Measures of biological aging could prove valuable for assessing patients' risk for physical and cognitive decline and for evaluating intervention effectiveness.
- |||||||||| Clinical guideline, Journal: Guidelines for Reasonable and Appropriate Care in the Emergency Department (GRACE-4): Alcohol use disorder and cannabinoid hyperemesis syndrome management in the emergency department. (Pubmed Central) - May 15, 2024
The SAEM GRACE-4 Writing Team, composed of emergency physicians and experts in addiction medicine and patients with lived experience, applied the Grading of Recommendations Assessment Development and Evaluation (GRADE) approach to assess the certainty of evidence and strength of recommendations regarding six priority questions for adult ED patients with AWS, AUD, and CHS. The SAEM GRACE-4 Writing Team reached the following recommendations: (1) in adult ED patients (over the age of 18) with moderate to severe AWS who are being admitted to hospital, we suggest using phenobarbital in addition to benzodiazepines compared to using benzodiazepines alone [low to very low certainty of evidence]; (2) in adult ED patients (over the age of 18) with AUD who desire alcohol cessation, we suggest a prescription for one anticraving medication [very low certainty of evidence]; (2a) in adult ED patients (over the age of 18) with AUD, we suggest naltrexone (compared to no prescription) to prevent return to heavy drinking [low certainty of evidence]; (2b) in adult ED patients (over the age of 18) with AUD and contraindications to naltrexone, we suggest acamprosate (compared to no prescription) to prevent return to heavy drinking and/or to reduce heavy drinking [low certainty of evidence]; (2c) in adult ED patients (over the age of 18) with AUD, we suggest gabapentin (compared to no prescription) for the management of AUD to reduce heavy drinking days and improve alcohol withdrawal symptoms [very low certainty of evidence]; (3a) in adult ED patients (over the age of 18) presenting to the ED with CHS we suggest the use of haloperidol or droperidol (in addition to usual care/serotonin antagonists, e.g., ondansetron) to help with symptom management [very low certainty of evidence]; and (3b) in adult ED patients (over the age of 18) presenting to the ED with CHS, we also suggest offering the use of topical capsaicin (in addition to usual care/serotonin antagonists, e.g., ondansetron) to help with symptom management [very low certainty of evidence].
- |||||||||| haloperidol / Generic mfg.
Journal: D2/D3 dopamine supports the precision of mental state inferences and self-relevance of joint social outcomes. (Pubmed Central) - May 15, 2024
Haloperidol, compared with the placebo, enhanced the impact of partner behaviour on beliefs about the harmful intent of partners, and increased learning from recent encounters...Our data and model bridge theory between general and social accounts of value representation. We demonstrate initial evidence for the sensitivity of our model and short social paradigm to drug intervention and clinical dimensions, allowing distinctions between mechanisms that operate across traits and states.
- |||||||||| fluoxetine / Generic mfg.
Journal: Delivering biochemicals with precision using bioelectronic devices enhanced with feedback control. (Pubmed Central) - May 15, 2024
These experiments showcased consistent performance across diverse input signals, maintaining the current value near the reference with a relative error of less than 7% in all trials. Our findings underscore the potential of the developed controller to address challenges in bioelectronic device implementation, offering reliable precision in drug delivery strategies within the realm of precision medicine.
- |||||||||| blarcamesine (Anavex 2-73) / Anavex
Journal: Sigma Receptor Ligands Are Potent Antiprion Compounds that Act Independently of Sigma Receptor Binding. (Pubmed Central) - May 15, 2024
While the precise details of the mechanism of action of these molecules remain to be determined, the present work forms the basis for further investigation of these compounds in preclinical studies. Given the therapeutic utility of several of the tested compounds, including rimcazole and haloperidol for neuropsychiatric conditions, (+)-pentazocine for neuropathic pain, and the ongoing clinical trials of SA 4503 and ANAVEX2-73 for ischemic stroke and Alzheimer's disease, respectively, this work has immediate implications for the treatment of human prion disease.
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Enrollment change, Trial termination: Botox for the Treatment of Recurrent Chronic Exertional Compartment Syndrome (clinicaltrials.gov) - May 15, 2024
P4, N=1, Terminated,
Recruiting --> Active, not recruiting N=10 --> 1 | Suspended --> Terminated; issues with supplier of strength testing equipment, presumed to go out of business
|
